Current perspectives on potential role of albumin in neuroprotection

Reviews in the Neurosciences

Volumn 22, Issue 3, 2011, Pages 355-363

  Prajapati, Kanaiyalal D ^a   Sharma, Shyam S ^a   Roy, Nilanjan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

albumin; Alzheimer's disease; amyloid ?; cerebrospinal fluid; ischemic stroke; neuroprotection

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; HUMAN SERUM ALBUMIN; PLACEBO; ALBUMINOID; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; DRUG DOSE ESCALATION; GLIA CELL; HEMODILUTION; HUMAN; INTRACELLULAR SIGNALING; ISCHEMIA; MICROGLIA; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM;

ALBUMINS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; STROKE;

EID: 80051916417     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/RNS.2011.028     Document Type: Review

References (67)

1. Ahn, S.M., Byun, K., Cho, K., Kim, J.Y., Yoo, J.S., Kim, D., Paek, S.H., Kim, S.U., Simpson, R.J., and Lee B. (2008). Human microglial cells synthesize albumin in brain. PLoS One 3, e2829.
2. Arroyo, V. (2002). Review article: albumin in the treatment of liver diseases-new features of a classical treatment. Aliment Pharmacol. Ther. 16 (Suppl. 5), 1-5. (Pubitemid 41759556)
3. Baltanas, F.C., Weruaga, E., Valero, J., Recio, J.S., and Alonso J.R. (2009). Albumin attenuates DNA damage in primary-cultured neurons. Neurosci. Lett. 450, 23-26.
4. Belayev, L., Busto, R., Zhao, W., Clemens, J.A., and Ginsberg M.D. (1997a). Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J. Neurosurg. 87, 595-601. (Pubitemid 27430403)
5. Belayev, L., Zhao, W., Busto, R., and Ginsberg M.D. (1997b). Transient middle cerebral artery occlusion by intraluminal suture: I. Three-dimensional autoradiographic image-analysis of local cerebral glucose metabolism-blood flow interrelationships during ischemia and early recirculation. J. Cereb. Blood Flow Metab. 17, 1266-1280. (Pubitemid 27520118)
6. Belayev, L., Zhao, W., Pattany, P.M., Weaver, R.G., Huh, P.W., Lin, B., Busto, R., and Ginsberg M.D. (1998). Diffusion-weighted magnetic resonance imaging confi rms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 29, 2587-2599. (Pubitemid 28544011)
7. Belayev, L., Alonso, O.F., Huh, P.W., Zhao, W., Busto, R., and Ginsberg M.D. (1999a). Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J. Neurotrauma 16, 445-453. (Pubitemid 29297900)
8. Belayev, L., Saul, I., Huh, P.W., Finotti, N., Zhao, W., Busto, R., and Ginsberg M.D. (1999b). Neuroprotective effect of highdose albumin therapy against global ischemic brain injury in rats. Brain Res. 845, 107-111. (Pubitemid 29472375)
9. Belayev, L., Liu, Y., Zhao, W., Busto, R., and Ginsberg M.D. (2001). Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32, 553-560. (Pubitemid 32155250)
10. Belayev, L., Pinard, E., Nallet, H., Seylaz, J., Liu, Y., Riyamongkol, P., Zhao, W., Busto, R., and Ginsberg M.D. (2002). Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 33, 1077-1084. (Pubitemid 34293595)
11. Belayev, L., Saul, I., Busto, R., Danielyan, K., Vigdorchik, A., Khoutorova, L., and Ginsberg M.D. (2005). Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 36, 326-331. (Pubitemid 40170817)
12. Bento-Abreu, A., Velasco, A., Polo-Hernandez, E., Perez-Reyes, P.L., Tabernero, A., and Medina J.M. (2008). Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. J. Neurochem. 106, 1149-1159.
13. Bento-Abreu, A., Velasco, A., Polo-Hernandez, E., Lillo, C., Kozyraki, R., Tabernero, A., and Medina J.M. (2009). Albumin endocytosis via megalin in astrocytes is caveola-and Dab-1 dependent and is required for the synthesis of the neurotrophic factor oleic acid. J. Neurochem. 111, 49-60.
14. Biere, A.L., Ostaszewski, B., Stimson, E.R., Hyman, B.T., Maggio, J.E., and Selkoe D.J. (1996). Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 271, 32916-32922. (Pubitemid 27008725)
15. Boada, M., Ortiz, P., Anaya, F., Hernandez, I., Munoz, J., Nunez, L., Olazaran, J., Roca, I., Cuberas, G., Tarraga, L., et al. (2009). Amyloid-targeted therapeutics in Alzheimer?s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 22, 325-339.
16. Bohrmann, B., Tjernberg, L., Kuner, P., Poli, S., Levet-Trafi t, B., Naslund, J., Richards, G., Huber, W., Dobeli, H., and Nordstedt C. (1999). Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J. Biol. Chem. 274, 15990-15995.
17. Cole, D.J., Drummond, J.C., Osborne, T.N., and Matsumura J. (1990). Hypertension and hemodilution during cerebral ischemia reduce brain injury and edema. Am. J. Physiol. 259, H211-H217. (Pubitemid 20247736)
18. Emerson, T.E., Jr. (1989). Unique features of albumin: a brief review. Crit. Care Med. 17, 690-694.
19. Evans, T.W. (2002). Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol. Ther. 16 (Suppl. 5), 6-11. (Pubitemid 41759557)
20. Garcovich, M., Zocco, M.A., and Gasbarrini A. (2009). Clinical use of albumin in hepatology. Blood Transfus. 7, 268-277.
21. Ginsberg, M.D. (2008). Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363-389.
22. Ginsberg, M.D., Hill, M.D., Palesch, Y.Y., Ryckborst, K.J., and Tamariz D. (2006a). The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: Physiological responses and safety results. Stroke 37, 2100-2106. (Pubitemid 44309911)
23. Ginsberg, M.D., Palesch, Y.Y., and Hill M.D. (2006b). The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem. Soc. Trans. 34, 1323-1326. (Pubitemid 46769048)
24. Ginsberg, M.D., Palesch, Y.Y., Martin, R.H., Hill, M.D., Moy, C.S., Waldman, B.D., Yeatts, S.D., Tamariz, D., and Ryckborst K. (2011). The Albumin In Acute Stroke (ALIAS) Multicenter Clinical Trial: safety analysis of part 1 and rationale and design of part 2. Stroke 42, 119-127.
25. Gum, E.T., Swanson, R.A., Alano, C., Liu, J., Hong, S., Weinstein, P.R., and Panter S.S. (2004). Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke 35, 590-595. (Pubitemid 38174455)
26. Hacke, W., Donnan, G., Fieschi, C., Kaste, M., von Kummer, R., Broderick, J.P., Brott, T., Frankel, M., Grotta, J.C., Haley, E.C., Jr., et al. (2004). Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363, 768-774.
27. Hooper, C., Taylor, D.L., and Pocock J.M. (2005). Pure albumin is a potent trigger of calcium signalling and proliferation in microglia but not macrophages or astrocytes. J. Neurochem. 92, 1363-1376. (Pubitemid 40389206)
28. Huh, P.W., Belayev, L., Zhao, W., Busto, R., Saul, I., and Ginsberg M.D. (1998). The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res. 804, 105-113. (Pubitemid 28410484)
29. Italian Acute Stroke Study Group. (1988). Haemodilution in acute stroke: results of the Italian Haemodilution Trial. Lancet i, 318-321.
30. Ivens, S., Kaufer, D., Flores, L.P., Bechmann, I., Zumsteg, D., Tomkins, O., Seiffert, E., Heinemann, U., and Friedman A. (2007). TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130, 535-547. (Pubitemid 46181106)
31. Johanson, C.E., Duncan, J.A., 3rd, Klinge, P.M., Brinker, T., Stopa, E.G., and Silverberg G.D. (2008). Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 5, 10.
32. Juttler, E., Kohrmann, M., and Schellinger P.D. (2006). Therapy for early reperfusion after stroke. Nat. Clin. Pract. Cardiovasc. Med. 3, 656-663. (Pubitemid 44811525)
33. Korosue, K. and Heros, R.C. (1992). Mechanism of cerebral blood flow augmentation by hemodilution in rabbits. Stroke 23, 1487-1492; discussion 1492-1493.
34. Little, J.R., Slugg, R.M., Latchaw, J.P., Jr., and Lesser R.P. (1981). Treatment of acute focal cerebral ischemia with concentrated albumin. Neurosurgery 9, 552-558. (Pubitemid 12239563)
35. Liu, Y., Belayev, L., Zhao, W., Busto, R., Belayev, A., and Ginsberg M.D. (2001). Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur. J. Pharmacol. 428, 193-201. (Pubitemid 33000141)
36. Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., Ford, E., Furie, K., Go, A., Greenlund, K., et al. (2009). Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, e21-e181.
37. Longa, E.Z., Weinstein, P.R., Carlson, S., and Cummins R. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84-91. (Pubitemid 19040218)
38. Manning, T.J., Jr. and Sontheimer, H. (1997). Bovine serum albumin and lysophosphatidic acid stimulate calcium mobilization and reversal of cAMP-induced stellation in rat spinal cord astrocytes. Glia 20, 163-172. (Pubitemid 27253209)
39. Matsui, T., Sinyama, H., and Asano T. (1993). Benefi cial effect of prolonged administration of albumin on ischemic cerebral edema and infarction after occlusion of middle cerebral artery in rats. Neurosurgery 33, 293-300; comment 300. (Pubitemid 23230591)
40. Murphy, M.P. and LeVine, H., 3rd. (2010). Alzheimer?s disease and the amyloid-beta peptide. J. Alzheimers Dis. 19, 311-323.
41. Nadal, A., Sul, J.Y., Valdeolmillos, M., and McNaughton P.A. (1998). Albumin elicits calcium signals from astrocytes in brain slices from neonatal rat cortex. J. Physiol. 509, 711-716. (Pubitemid 28306135)
42. Nahon, J.L., Tratner, I., Poliard, A., Presse, F., Poiret, M., Gal, A., Sala-Trepat, J.M., Legres, L., Feldmann, G., and Bernuau D. (1988). Albumin and alpha-fetoprotein gene expression in various nonhepatic rat tissues. J. Biol. Chem. 263, 11436-11442.
43. Neugroschl, J. and Sano, M. (2010). Current treatment and recent clinical research in Alzheimer?s disease. Mt. Sinai J. Med. 77, 3-16.
44. Nicholson, J.P., Wolmarans, M.R., and Park G.R. (2000). The role of albumin in critical illness. Br. J. Anaesth. 85, 599-610.
45. Nimmagadda, A., Park, H.P., Prado, R., and Ginsberg M.D. (2008). Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laserscanning microscopy study. Stroke 39, 198-204.
46. Palesch, Y.Y., Hill, M.D., Ryckborst, K.J., Tamariz, D., and Ginsberg M.D. (2006). The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: neurologic outcome and efficacy analysis. Stroke 37, 2107-2114. (Pubitemid 44309912)
47. Prajapati, K.D., Sharma, S.S., and Roy N. (2010). Upregulation of albumin expression in focal ischemic rat brain. Brain Res. 1327, 118-124.
48. Quinlan, G.J., Martin, G.S., and Evans T.W. (2005). Albumin: biochemical properties and therapeutic potential. Hepatology 41, 1211-1219. (Pubitemid 40770271)
49. Ralay Ranaivo, H. and Wainwright, M.S. (2010). Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. Brain Res. 1313, 222-231.
50. Reiber, H. (1998). Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult. Scler. 4, 99-107. (Pubitemid 28410032)
51. Reiber, H. (2003). Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor. Neurol. Neurosci. 21, 79-96. (Pubitemid 37330250)
52. Reiber, H. and Peter, J.B. (2001). Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 184, 101-122. (Pubitemid 32178265)
53. Remmers, M., Schmidt-Kastner, R., Belayev, L., Lin, B., Busto, R., and Ginsberg M.D. (1999). Protein extravasation and cellular uptake after high-dose human-albumin treatment of transient focal cerebral ischemia in rats. Brain Res. 827, 237-242. (Pubitemid 29222928)
54. Rodriguez de Turco, E.B., Belayev, L., Liu, Y., Busto, R., Parkins, N., Bazan, N.G., and Ginsberg M.D. (2002). Systemic fatty acid responses to transient focal cerebral ischemia: Influence of neuroprotectant therapy with human albumin. J. Neurochem. 83, 515-524. (Pubitemid 35231805)
55. rt-PA Stroke Study Group. (1995). Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587.
56. Scandinavian Stroke Study Group. (1987). Multicenter trial of hemodilution in acute ischemic stroke. I. Results in the total patient population. Stroke 18, 691-699.
57. Selkoe, D.J. (1991). The molecular pathology of Alzheimer?s disease. Neuron 6, 487-498.
58. Sundt, T.M., Jr., Waltz, A.G., and Sayre G.P. (1967). Experimental cerebral infarction: modification by treatment with hemodiluting, hemoconcentrating, and dehydrating agents. J. Neurosurg. 26, 46-56.
59. Swerdlow, R.H., Burns, J.M., and Khan S.M. (2010). The Alzheimer?s disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20 (Suppl. 2), S265-S279.
60. Tabernero, A., Medina, A., Sanchez-Abarca, L.I., Lavado, E., and Medina J.M. (1999). The effect of albumin on astrocyte energy metabolism is not brought about through the control of cytosolic Ca2 + concentrations but by free-fatty acid sequestration. Glia 25, 1-9. (Pubitemid 28554051)
61. Tabernero, A., Velasco, A., Granda, B., Lavado, E.M., and Medina J.M. (2002). Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J. Biol. Chem. 277, 4240-4246. (Pubitemid 34968687)
62. Tang, J., Li, Y.J., Mu, J., Li, Q., Yang, D.Y., and Xie P. (2009). Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats. Neurol. Res. 31, 189-194.
63. The Hemodilution in Stroke Study Group. (1989). Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. Stroke 20, 317-323.
64. Tilghman, S.M. and Belayew, A. (1982). Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc. Natl. Acad. Sci. USA 79, 5254-5257.
65. van Vliet, E.A., da Costa Araujo, S., Redeker, S., van Schaik, R., Aronica, E., and Gorter J.A. (2007). Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130, 521-534. (Pubitemid 46181105)
66. Wood, J.H. and Kee, D.B., Jr. (1985). Hemorheology of the cerebral circulation in stroke. Stroke 16, 765-772. (Pubitemid 15246744)
67. Yao, X., Miao, W., Li, M., Wang, M., Ma, J., Wang, Y., Miao, L., and Feng H. (2010). Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. Neurosci. Lett. 472, 179-183.